LFVN Lifevantage Corp
Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%
Margins
Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%
Returns
ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $182.59M | $228.53M | $200.16M | $213.40M | $206.36M |
| Cost of revenue | $40.97M | $44.86M | $41.44M | $43.39M | $38.10M |
| Gross profit | $141.61M | $183.67M | $158.72M | $170.01M | $168.26M |
| R&D expense | $1.00M | $1.40M | $700,000 | $600,000 | $700,000 |
| SG&A expense | $58.42M | $69.21M | $68.47M | $71.06M | $63.42M |
| Operating income | $6.10M | $12.20M | $4.33M | $4.26M | $7.58M |
| Interest expense | — | — | -$430,000 | -$198,000 | $10,000 |
| Pretax income | $6.07M | $12.24M | $4.35M | $4.00M | $4.69M |
| Income tax | $994,000 | $2.44M | $1.41M | $1.46M | $1.57M |
| Net income | $5.07M | $9.80M | $2.94M | $2.54M | $3.12M |
| EBITDA | $8.87M | $15.36M | $7.91M | $7.84M | $10.84M |
| EPS (basic) | 0.40 | 0.80 | 0.24 | 0.20 | 0.24 |
| EPS (diluted) | 0.40 | 0.75 | 0.23 | 0.20 | 0.24 |
| Dividends declared per share | 0.18 | 0.17 | 0.55 | 0.12 | 0.03 |
| Weighted avg. shares (diluted) | 12.70M | 12.99M | 12.99M | 12.57M | 13.07M |
| Balance sheet | |||||
| Cash & equivalents | $14.92M | $20.20M | $16.89M | $21.61M | $20.19M |
| Receivables | $2.99M | $3.29M | $2.95M | $1.61M | $3.34M |
| Inventory | $16.17M | $20.67M | $15.05M | $16.07M | $16.47M |
| Current assets | $38.30M | $50.89M | $37.65M | $44.28M | $46.96M |
| PP&E, net | $7.31M | $6.21M | $7.81M | $9.09M | $9.50M |
| Goodwill | $465,000 | $0 | — | — | — |
| Intangibles | $3.06M | $245,000 | $323,000 | $455,000 | $587,000 |
| Total assets | $62.11M | $71.96M | $60.30M | $66.12M | $70.71M |
| Current liabilities | $20.23M | $27.22M | $22.31M | $19.61M | $25.73M |
| Total liabilities | $28.52M | $37.32M | $34.31M | $31.47M | $39.19M |
| Shareholders' equity | $33.59M | $34.64M | $25.99M | $34.65M | $31.52M |
| Shares outstanding | 12.52M | 12.43M | 12.51M | 12.62M | 12.49M |
| Cash flow statement | |||||
| Operating cash flow | $10.24M | $11.88M | $12.20M | $6.83M | $7.96M |
| Capital expenditure | $3.57M | $1.37M | $2.25M | $3.07M | $1.53M |
| Free cash flow | $6.67M | $10.51M | $9.95M | $3.76M | $6.43M |
| Investing cash flow | -$7.31M | -$1.37M | -$2.25M | -$3.06M | -$1.53M |
| Financing cash flow | -$7.78M | -$7.60M | -$14.42M | -$2.36M | -$8.95M |
| Depreciation & amortization | $2.77M | $3.16M | $3.58M | $3.58M | $3.26M |
| Stock-based compensation | $2.35M | $5.70M | $3.28M | $3.19M | $1.77M |
| Dividends paid | $2.34M | $2.07M | $6.94M | $1.59M | $378,000 |
| Share buybacks | $2.04M | $3.15M | $6.43M | $822,000 | $8.83M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.